ESMO-MCBS
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
See you in Berlin to network and share ideas at this dedicated event for the breast cancer community
Gain deeper understanding and register for the ESMO Deep Dive: Breast Cancer webinar, available to all ESMO members.
Save the date for a unique opportunity to connect with world renowned experts discussing the latest trials in advanced breast cancer and high-risk GIST
Last days to submit your studies to an international audience of leading oncology professionals, researchers and industry experts
Join us in London from October 16th to 18th for this global gathering focused on precision oncology and translational research. Engage in networking and discussions on the latest groundbreaking data in the field.
Experience the forefront of Asian and global oncology at ESMO Asia 2024, 6-8 December, Singapore. Connect, learn, and innovate in multidisciplinary cancer care.
Join us for a dynamic exchange of ideas, breakthrough discoveries, and transformative strategies
These annual four-day residential courses provide insight into the field of medical oncology, enabling participants to get a better picture before making the choice of their specialisation
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Genomic and tumour microenvironment parameters associated with response to PD1 blockade in dMMR cancers
Expanding the guide’s availability in more languages
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
Evidence for efficacy is based on the results from the FIREFLY-1 study
Ahead of the plenary vote in the European Parliament (EP), held on 10 April 2024, ESMO wrote to the Political Groups Coordinators on the EP’s Committee on the Environment, Public Health and Food Safety (ENVI) to welcome its reports as a positive step towards reforming the European Union’s general pharmaceutical legislation, as it provides a once in a generation opportunity to improve the availability, accessibility and affordability of medicines for both cancer and rare cancer patients in the EU
Expanding the guide’s availability in more languages
Findings from subgroup analyses of the DESTINY-Breast03 study
Merkel-cell carcinoma is a rare primary neuroendocrine carcinoma of the skin, which exhibits agressive behaviour with a high recurrence rate and a propensity for early metastasis. This Clinical Practice Guideline aims to provide a comprehensive reference and is based on a critical evaluation of current evidence and expert opinion.
It is intended for the treatment of patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations
Genomic and tumour microenvironment parameters associated with response to PD1 blockade in dMMR cancers
Evidence for efficacy is based on the results from the FIREFLY-1 study
Findings from subgroup analyses of the DESTINY-Breast03 study
It is intended for the treatment of patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations
AI model TORCH achieved robust performance
Evidence for efficacy is based on the results from the QUILT-3.032 study
Evidence for efficacy is based on the results from the ALINA study
Findings from the KEYNOTE-564 study
Findings from the Young Women’s Breast Cancer Study
The European Lung Cancer Congress 2024 is the annual appointment that brings together various experts in the field of thoracic oncology
The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general
The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care
Experts predict death rates from all cancers for the EU and UK for 2024
The ESMO Immuno-Oncology Congress 2023, where experts discuss the latest scientific developments in this fast-moving field of cancer treatment, will be held in Geneva, Switzerland, between 6-8 December, also with a virtual component
The ESMO Asia Congress 2023 is the annual meeting to present and discuss the latest scientific and clinical advances across the entire field of oncology, of relevance at a global level and specifically for the Asia-Pacific region.
Evidence is building up that strong political action has the potential to tackle two of our era’s biggest challenges: climate change and the increasing burden of cancer on society
As the ESMO Congress 2023 opens its doors in Madrid this week, ESMO calls all EU member states to act on the recently adopted final text of the EU Consumer Credits Directive by following their European neighbours Spain and France and guaranteeing cancer survivors seeking financial credit the so-called right to be forgotten after a period of five years following the end of their treatment
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new data that cover the entire spectrum of managing patients with cervical cancer, will be presented at the ESMO Congress 2023 in Madrid, Spain
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
The European Society for Medical Oncology (ESMO) announced today that the 2024 Heine H. Hansen Award is bestowed to Enriqueta Felip
The nomination process for the 2024 ESMO Society Awards is now open
ESMO is pleased to announce the newly appointed Committee and Working Group Chairs who started their mandates in January 2024
The European Society for Medical Oncology (ESMO) has announced today that the 2024 ESMO TAT Honorary Award is bestowed to Funda Meric-Bernstam
ESMO is pleased to announce the renewal of its status as non-State actor in official relations with the World Health Organization - a privilege granted to non-governmental organisations, which recognises ESMO’s sustained and systematic engagement in the interest of the WHO
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
As the world observes Universal Health Coverage Day, ESMO anticipates the results of the latest study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines, highlighting a worrying stall over the last five years
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy
Universal health coverage in oncology is still not a reality, as a recent report shows
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.